A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
Public ClinicalTrials.gov record NCT05823974. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Randomized, Dose-finding/Dose-confirmation Study to Evaluate the Reactogenicity, Safety and Immunogenicity of mRNA-based Multivalent Seasonal Influenza Vaccine Candidates Administered in Healthy Younger and Older Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A) candidates administered in healthy younger and older adults (OA).
Study identification
- NCT ID
- NCT05823974
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 1,275 participants
Conditions and interventions
Conditions
Interventions
- F2C22C/DL001Z Biological
- F2B22A/DL001Z Biological
- F2B22B/DL001Z Biological
- F2B22C/DL001Z Biological
- F2B22D/DL001Z Biological
- F2B22E/DL001Z Biological
- F2F22A/DL001Z Biological
- F2F22B/DL001Z Biological
- F2F22C/DL001Z Biological
- F2F22D/DL001Z Biological
- F2F22E/DL001Z Biological
- Control 1 Combination Product
- F2F23D/DL001Z-NH Biological
- F2F23A/DL001Z-NH Biological
- F2F23B/DL001Z-NH Biological
- Control 2 Combination Product
- F2F23C/DL001Z-NH Biological
- Control 3 Combination Product
- F2F22F/DL001Z Biological
Biological · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 27, 2023 (Actual)
- Primary completion
- Jul 2, 2024 (Actual)
- Completion
- Dec 18, 2024 (Actual)
- Last update posted
- Jul 23, 2025
2023 – 2024
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Hialeah | Florida | 33012 | — |
| GSK Investigational Site | Miami | Florida | 33186 | — |
| GSK Investigational Site | Chicago | Illinois | 60640 | — |
| GSK Investigational Site | Valparaiso | Indiana | 46383 | — |
| GSK Investigational Site | Lenexa | Kansas | 66219 | — |
| GSK Investigational Site | Wichita | Kansas | 67207 | — |
| GSK Investigational Site | Lexington | Kentucky | 40509 | — |
| GSK Investigational Site | Boston | Massachusetts | 02215 | — |
| GSK Investigational Site | Dearborn | Michigan | 48127 | — |
| GSK Investigational Site | Papillion | Nebraska | 68046 | — |
| GSK Investigational Site | Rochester | New York | 14609 | — |
| GSK Investigational Site | Syracuse | New York | 13057 | — |
| GSK Investigational Site | Denver | North Carolina | 80110 | — |
| GSK Investigational Site | Greensboro | North Carolina | 27408 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27612 | — |
| GSK Investigational Site | Wilmington | North Carolina | 28401 | — |
| GSK Investigational Site | Dayton | Ohio | 33147 | — |
| GSK Investigational Site | East Greenwich | Rhode Island | 02818 | — |
| GSK Investigational Site | Knoxville | Tennessee | 37909 | — |
| GSK Investigational Site | Fort Worth | Texas | 76135 | — |
| GSK Investigational Site | Houston | Texas | 48076 | — |
| GSK Investigational Site | Tomball | Texas | 77375 | — |
| GSK Investigational Site | Newport News | Virginia | 23606 | — |
| GSK Investigational Site | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05823974, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 23, 2025 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05823974 live on ClinicalTrials.gov.